Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803-Reference-Cited by-同舟云学术

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

Published:2011-05 Issue:7 Volume:47 Page:990-996
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sargent D.,Shi Q.,Yothers G.,Van Cutsem E.,Cassidy J.,Saltz L.,Wolmark N.,Bot B.,Grothey A.,Buyse M.,de Gramont A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma;Moertel;N Engl J Med,1990

2. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20, 898 patients on 18 randomized trials;Sargent;J Clin Oncol,2009

3. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials;Sargent;J Clin Oncol,2005

4. End-points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group;Sargent;J Clin Oncol,2007

5. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy;Kopetz;J Clin Oncol,2009

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months;European Journal of Cancer;2024-09

2. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers;Annals of Surgery;2023-08-28

3. Association between event-free survival and overall survival in early-stage triple-negative breast cancer;Future Oncology;2023-08-21

4. pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients—An Updated Pooled Analysis of Eleven International Randomized Trials;Cancers;2023-06-16

5. Navigating treatment options for sacral spine lymphoma: A medical journey;International Journal of Surgery Case Reports;2023-06